Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults

Review decison: May 2012 information

Appendix A - Decision paper presented to the Institute's Guidance Executive (PDF 66 KB)

Venous thromboembolism - rivaroxaban: review proposal - February 2012 information

Appendix A: provisional matrix of stakeholders (PDF 65 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 212 KB)

2009/030 NICE appraisal of rivaroxaban for the prevention of venous thromboembolism after surgery (PDF 31 KB)

Venous thromboembolism - rivaroxaban: final appraisal determination  information

Venous thromboembolism - rivaroxaban: final appraisal determination (PDF 89 KB)

Venous thromboembolism - rivaroxaban: non-manufacturer submissions

Royal College of Nursing (PDF 72 KB)

British Society for Haemostasis and Thrombosis (PDF 29 KB)

Bayer Healthcare (PDF 1.07 MB)

Venous thromboembolism - rivaroxaban: clarification letters

NICE clarification letter 1 (PDF 30 KB)

Manufacturer response to clarification letter 1 (PDF 333 KB)

NICE clarification letter 2 (PDF 27 KB)

Manufacturer response to clarification letter 2 (PDF 52 KB)

Venous thromboembolism - rivaroxaban: expert written personal statements

Mr Colin Howie (PDF 25 KB)

Professor Mike Laffan (PDF 33 KB)

Eve Knight (PDF 111 KB)

Annya Stevens - Boal (PDF 34 KB)

Venous thromboembolism - rivaroxaban: ERG report (PDF 190 KB)

Venous thromboembolism - rivaroxaban: final scope (PDF 29 KB)

Venous thromboembolism - rivaroxaban: final matrix of consultees and commentators (list of stakeholders) (PDF 31 KB)

Venous thromboembolism - rivaroxaban: response to comments on the draft scope (PDF 84 KB)

Venous thromboembolism - rivaroxaban: response to comments on the provisional matrix (PDF 22 KB)